Interferon Lambda: a New Sword in Cancer Immunotherapy

Overview

Journal Clin Dev Immunol

Specialty Allergy & Immunology

Date 2011 Dec 23

PMID 22190970

Citations 41

Authors

Ahmed Lasfar

Walid Abushahba

Murugabaskar Balan

Karine A Cohen-Solal

Affiliations

Soon will be listed here.

Abstract

The discovery of the interferon-lambda (IFN-λ) family has considerably contributed to our understanding of the role of interferon not only in viral infections but also in cancer. IFN-λ proteins belong to the new type III IFN group. Type III IFN is structurally similar to type II IFN (IFN-γ) but functionally identical to type I IFN (IFN-α/β). However, in contrast to type I or type II IFNs, the response to type III IFN is highly cell-type specific. Only epithelial-like cells and to a lesser extent some immune cells respond to IFN-λ. This particular pattern of response is controlled by the differential expression of the IFN-λ receptor, which, in contrast to IFN-α, should result in limited side effects in patients. Recently, we and other groups have shown in several animal models a potent antitumor role of IFN-λ that will open a new challenging era for the current IFN therapy.

Citing Articles

Unveiling the therapeutic prospects of IFNW1 and IFNA21: insights into glioma pathogenesis and clinical significance.

Cheng H, Zhao Y, Hou X, Ling F, Wang J, Wang Y Neurogenetics. 2024; 25(4):337-350.

PMID: 38958838 DOI: 10.1007/s10048-024-00769-5.

The Immunotherapeutic Role of Type I and III Interferons in Melanoma and Non-Melanoma Skin Cancers.

Weir S, Kc K, Shoaib S, Yusuf N Life (Basel). 2023; 13(6).

PMID: 37374093 PMC: 10303590. DOI: 10.3390/life13061310.

Enhanced soluble expression of active recombinant human interleukin-29 using champion pET SUMO system.

Munir A, Ahmed N, Akram M, Fujimura N, Tahir S, Malik K Biotechnol Lett. 2023; 45(8):1001-1011.

PMID: 37266881 PMC: 10235849. DOI: 10.1007/s10529-023-03402-x.

Type 1-type 2 interferon imbalance in dry eye disease.

Panigrahi T, DSouza S, Babu V, Dickman M, Nuijts R, Sethu S Indian J Ophthalmol. 2023; 71(4):1526-1532.

PMID: 37026295 PMC: 10276729. DOI: 10.4103/IJO.IJO_2842_22.

Unraveling the Complex Interconnection between Specific Inflammatory Signaling Pathways and Mechanisms Involved in HIV-Associated Colorectal Oncogenesis.

Damane B, Mulaudzi T, Kader S, Naidoo P, Savkovic S, Dlamini Z Cancers (Basel). 2023; 15(3).

PMID: 36765706 PMC: 9913377. DOI: 10.3390/cancers15030748.

References

Mangia A, Thompson A, Santoro R, Piazzolla V, Tillmann H, Patel K . An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology. 2010; 139(3):821-7, 827.e1. DOI: 10.1053/j.gastro.2010.05.079. View

Ank N, Iversen M, Bartholdy C, Staeheli P, Hartmann R, Jensen U . An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J Immunol. 2008; 180(4):2474-85. DOI: 10.4049/jimmunol.180.4.2474. View

El-Serag H . Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol. 2002; 35(5 Suppl 2):S72-8. DOI: 10.1097/00004836-200211002-00002. View

Sommereyns C, Paul S, Staeheli P, Michiels T . IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog. 2008; 4(3):e1000017. PMC: 2265414. DOI: 10.1371/journal.ppat.1000017. View

Srinivas S, Dai J, Eskdale J, Gallagher G, Megjugorac N, Gallagher G . Interferon-lambda1 (interleukin-29) preferentially down-regulates interleukin-13 over other T helper type 2 cytokine responses in vitro. Immunology. 2008; 125(4):492-502. PMC: 2612545. DOI: 10.1111/j.1365-2567.2008.02862.x. View

Thomas C, Moraga I, Levin D, Krutzik P, Podoplelova Y, Trejo A . Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell. 2011; 146(4):621-32. PMC: 3166218. DOI: 10.1016/j.cell.2011.06.048. View

Moschos S, Varanasi S, Kirkwood J . Interferons in the treatment of solid tumors. Cancer Treat Res. 2005; 126:207-41. DOI: 10.1007/0-387-24361-5_9. View

Omata M, Yoshida H, Shiratori Y . Prevention of hepatocellular carcinoma and its recurrence in chronic hepatitis C patients by interferon therapy. Clin Gastroenterol Hepatol. 2005; 3(10 Suppl 2):S141-3. DOI: 10.1016/s1542-3565(05)00713-5. View

Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst S, Otte J . IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am J Physiol Gastrointest Liver Physiol. 2005; 289(5):G960-8. DOI: 10.1152/ajpgi.00126.2005. View

10.

Kalvakolanu D . The GRIMs: a new interface between cell death regulation and interferon/retinoid induced growth suppression. Cytokine Growth Factor Rev. 2004; 15(2-3):169-94. DOI: 10.1016/j.cytogfr.2004.01.002. View

11.

Biron C . Interferons alpha and beta as immune regulators--a new look. Immunity. 2001; 14(6):661-4. DOI: 10.1016/s1074-7613(01)00154-6. View

12.

Wolk K, Witte K, Witte E, Proesch S, Schulze-Tanzil G, Nasilowska K . Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. J Leukoc Biol. 2008; 83(5):1181-93. DOI: 10.1189/jlb.0807525. View

13.

Morrow M, Pankhong P, Laddy D, Schoenly K, Yan J, Cisper N . Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood. 2009; 113(23):5868-77. PMC: 2700323. DOI: 10.1182/blood-2008-11-190520. View

14.

Javelaud D, Alexaki V, Mauviel A . Transforming growth factor-beta in cutaneous melanoma. Pigment Cell Melanoma Res. 2008; 21(2):123-32. DOI: 10.1111/j.1755-148X.2008.00450.x. View

15.

Dumoutier L, Tounsi A, Michiels T, Sommereyns C, Kotenko S, Renauld J . Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J Biol Chem. 2004; 279(31):32269-74. DOI: 10.1074/jbc.M404789200. View

16.

Witte K, Gruetz G, Volk H, Looman A, Asadullah K, Sterry W . Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun. 2009; 10(8):702-14. DOI: 10.1038/gene.2009.72. View

17.

Kelly C, Klenerman P, Barnes E . Interferon lambdas: the next cytokine storm. Gut. 2011; 60(9):1284-93. PMC: 3152870. DOI: 10.1136/gut.2010.222976. View

18.

Kaido T, Maury C, Schirrmacher V, GRESSER I . Successful immunotherapy of the highly metastatic murine ESb lymphoma with sensitized CD8+ T cells and IFN-alpha/beta. Int J Cancer. 1994; 57(4):538-43. DOI: 10.1002/ijc.2910570417. View

19.

Abushahba W, Balan M, Castaneda I, Yuan Y, Reuhl K, Raveche E . Antitumor activity of type I and type III interferons in BNL hepatoma model. Cancer Immunol Immunother. 2010; 59(7):1059-71. PMC: 4699672. DOI: 10.1007/s00262-010-0831-3. View

20.

Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate M . IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009; 41(10):1100-4. DOI: 10.1038/ng.447. View